Literature DB >> 9159186

Transgenic approaches for the reduction of Galalpha(1,3)Gal for xenotransplantation.

M S Sandrin1, N Osman, I F McKenzie.   

Abstract

The major barrier to clinically successful xenotransplantation is the lack of effective therapies aimed at eliminating antibody and complement -dependent hyperacute rejection. This review examines transgenic strategies to eliminate or reduce expression of the major pig to human xenoantigen Galalpha(1,3)Gal such that the epitope is no longer recognized by natural human antibodies, by the use of glycosidases and/or glycosyltransferases that can competitively and effectively inhibit the activity of the alpha1,3galactosyltransferase gene and thereby eliminate the xenoantigen Galalpha(1,3)Gal.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9159186     DOI： 10.2741/a220

Source DB:  PubMed          Journal:  Front Biosci        ISSN： 1093-4715


  5 in total

1.  Carrageenan-induced NFkappaB activation depends on distinct pathways mediated by reactive oxygen species and Hsp27 or by Bcl10.

Authors:  Sumit Bhattacharyya; Pradeep K Dudeja; Joanne K Tobacman
Journal:  Biochim Biophys Acta       Date:  2008-04-11

2.  Carrageenan-induced innate immune response is modified by enzymes that hydrolyze distinct galactosidic bonds.

Authors:  Sumit Bhattacharyya; Haiying Liu; Zhenqing Zhang; Murielle Jam; Pradeep K Dudeja; Gurvan Michel; Robert J Linhardt; Joanne K Tobacman
Journal:  J Nutr Biochem       Date:  2009-10-28       Impact factor: 6.048

3.  Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells.

Authors:  Sumit Bhattacharyya; Ravinder Gill; Mei Ling Chen; Fuming Zhang; Robert J Linhardt; Pradeep K Dudeja; Joanne K Tobacman
Journal:  J Biol Chem       Date:  2008-02-05       Impact factor: 5.157

4.  A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity.

Authors:  Sumit Bhattacharyya; Theresa Shumard; Hui Xie; Amar Dodda; Krista A Varady; Leo Feferman; Allan G Halline; Jay L Goldstein; Stephen B Hanauer; Joanne K Tobacman
Journal:  Nutr Healthy Aging       Date:  2017-03-31

Review 5.  Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review).

Authors:  Guoli Huai; Ping Qi; Hongji Yang; Yi Wang
Journal:  Int J Mol Med       Date:  2015-10-30       Impact factor: 4.101
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.